Streetbeat News

Analyst Ratings

SUPN

Piper Sandler has downgraded Supernus Pharmaceuticals from Overweight to Neutral and reduced its price target from $41 to $36.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:41 am

AR

Wolfe Research has upgraded Antero Resources to 'Outperform' with a new price target of $37, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:37 am

CAC

Keefe, Bruyette & Woods has maintained a Market Perform rating on Camden National (NASDAQ:CAC) and raised the price target from $40 to $41.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:36 am

ROIV

HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Roivant Sciences (NASDAQ:ROIV) and maintained a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:32 am

POWI

Benchmark analyst David Williams has reiterated a Buy rating on Power Integrations (NASDAQ:POWI) and maintained a price target of $78.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:29 am

NVS

B of A Securities has downgraded Novartis from Buy to Neutral and reduced its price target from $135 to $130.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:29 am

ACET

HC Wainwright & Co. has downgraded Adicet Bio (NASDAQ:ACET) from Buy to Neutral, as per analyst Edward White.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:18 am

LXRX

HC Wainwright & Co. has reiterated its Buy rating for Lexicon Pharmaceuticals, maintaining a price target of $10. Analyst Joseph Pantginis continues to support the stock, indicating confidence in its potential growth.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:13 am

LCID

Needham analyst Chris Pierce has reiterated a Hold rating on Lucid Group (NASDAQ:LCID).

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:08 am

STOK

HC Wainwright & Co. has reiterated its Buy rating for Stoke Therapeutics, maintaining a price target of $35. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2024 | 10:07 am